Skip to main content

Table 3 Concomitant antimicrobial therapy in clinically evaluable population

From: Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial

Parameter

Infusion group

(n= 106)

Bolus group

(n= 108)

P- value

Any

51 (48.1%)

55 (50.9%)

0.685

Penicillins

11 (10.4%)

5 (4.6%)

0.126

penicillin G

3

1

0.367

oxacillin

4

2

0.443

piperacillin/tazobactam

4

2

0.443

Aminoglycosides

4 (3.8%)

1 (0.9%)

0.210

Fluoroquinolones

6 (5.7%)

3 (2.8%)

0.330

Vancomycin

4 (3.8%)

11 (10.2%)

0.106

Linezolid

11 (10.4%)

7 (6.5%)

0.335

Metronidazole

7 (6.6%)

13 (12.0%)

0.240

Antifungals

34 (32.1%)

30 (27.6%)

0.551

  1. Values are presented as absolute (percentage).